AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) shares traded up 8.1% during trading on Wednesday . The stock traded as high as $27.00 and last traded at $26.96, with a volume of 668,312 shares. The stock had previously closed at $24.95.

Several research analysts recently commented on the stock. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $37.00 target price on shares of AMAG Pharmaceuticals in a research note on Thursday, May 5th. Jefferies Group reaffirmed a “buy” rating on shares of AMAG Pharmaceuticals in a research note on Wednesday, May 4th. Raymond James Financial Inc. downgraded shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 4th. Leerink Swann reaffirmed an “outperform” rating on shares of AMAG Pharmaceuticals in a research note on Saturday, April 16th. Finally, Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $38.20.

The firm has a market cap of $930.15 million and a PE ratio of 89.97. The company’s 50 day moving average price is $24.25 and its 200 day moving average price is $23.48.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.94 EPS for the quarter, missing analysts’ consensus estimates of $1.11 by $0.17. The firm earned $117.60 million during the quarter, compared to analysts’ expectations of $124.83 million. The business’s revenue was up 41.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.17 EPS. On average, equities analysts forecast that AMAG Pharmaceuticals Inc. will post $5.20 earnings per share for the current year.

Several hedge funds and institutional investors have recently bought and sold shares of AMAG. Rhumbline Advisers increased its position in AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock worth $1,131,000 after buying an additional 3,420 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its stake in shares of AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock worth $1,498,000 after buying an additional 42,208 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock worth $1,893,000 after buying an additional 3,903 shares in the last quarter. Bank of Montreal Can increased its stake in shares of AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock worth $2,287,000 after buying an additional 73,152 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of AMAG Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 397,816 shares of the specialty pharmaceutical company’s stock worth $12,010,000 after buying an additional 8,435 shares in the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.